Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment

J.Cortes; K.Gelmon; P.Fumoleau; A.Wardley; S.Verma; P.F.Conte; L.Gianni; S.J.Kirk; V.McNally; J.Baselga

首页> 外文期刊>European Journal of Cancer Supplements >Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment

【24h】

Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment

机译：曲妥珠单抗联合培妥珠单抗治疗在曲妥珠单抗治疗期间进展的HER2阳性转移性乳腺癌患者中的有效性和安全性的第二阶段评估

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2008年第7期|共1页
作者
J.Cortes; K.Gelmon; P.Fumoleau; A.Wardley; S.Verma; P.F.Conte; L.Gianni; S.J.Kirk; V.McNally; J.Baselga;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase II, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxe! in Patients With Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla2期

机译：II期，随机，双盲，安慰剂对照的注册试验，用于评估帕妥珠单抗+曲妥珠单抗+多西他赛与安慰剂+曲妥珠单抗+多西他赛的疗效和安全性！未经治疗的HER2阳性转移性乳腺癌（CLEOPATRA）患者中
2. The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program [J] . Pivot X., Poole C., Martin M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：具有或不含化疗或患者（PTS）的皮下曲据（PTS）与HER2阳性早期乳腺癌（EBC）或转移性乳腺癌（MBC）的开放标签，跨国，多中心，阶段IIIB伞研究，包括（PTS）（MBC）：安全数据的汇总分析来自Umbher1程序
3. Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：pertuzumab（p）加上高剂量曲妥珠单抗（h）用于治疗患者（pts）中的放射治疗（pts）后的中枢神经系统（CNS）进展，HER2阳性转移性乳腺癌（MBC）：主要疗效分析结果第II期Patricia研究
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）
7. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [O] . Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, 2018

机译：在Her2-阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，先前用Pertuzumab，Trastuzumab和化疗治疗：日本乳腺癌研究组-M05珍贵研究

Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment

著录项

相似文献

相关主题

期刊订阅